In 1999, the first rotavirus vaccine licensed in the USA was withdrawn 9 months after
introduction due to an association with intussusception that was detected in post-licensure …

The association between the first oral rotavirus vaccine to be licensed in the US
(Rotashield®) and intussusception has presented a major challenge to the effort to reduce …

Two live oral rotavirus vaccines (RotaTeq® and Rotarix®) have recently been
recommended by the WHO for inclusion into the national immunization programs of …

Currently available rotavirus vaccines have been associated with a small increased risk of
intussusception (∼ 1–2 cases per 100,000 vaccinated infants) in some populations. In …

Background International post-licensure studies on rotavirus vaccines have identified an
increased risk of intussusception in infants after administration. The first developed rotavirus …

Background: Postlicensure surveillance studies suggest a small temporal increase in the
risk for intussusception with both currently available rotavirus vaccines (RV1; Rotarix, GSK …

INTRODUCTION: In Australia, post-marketing surveillance for intussusception following
vaccination commenced with funding of RotaTeq® and Rotarix® vaccines under the …

Rotavirus vaccines have substantially decreased rotavirus hospitalizations in countries
where they have been implemented. In some high-and middle-income countries, a low-level …

Background Although current rotavirus vaccines were not associated with an increased risk
of intussusception in large trials before licensure, recent postlicensure data from …

As of January 2016, 80 countries have introduced rotavirus vaccines into their national
immunization programs. Many have documented significant declines in rotavirus-specific …